LinkedIn “Likes” Trigger Investigation of Pharma Giants

In the digital age, LinkedIn has become a key channel for companies to communicate with the public. However, in certain cases, this channel can also present ethical and regulatory compliance challenges, particularly in the highly regulated pharmaceutical industry. Recently, investigations by the UK’s Prescription Medicines Code of Practice Authority (PMCPA) have put pharmaceutical giants AstraZeneca and GlaxoSmithKline (GSK) in the spotlight. This incident not only reveals the strictness of compliance overseas but also piques the author's interest.

The incident began simply: several employees of AstraZeneca in the UK (reportedly including senior management) liked a post on LinkedIn mentioning the company's cancer drug Tagrisso. Although the post was initially described as "non-promotional content," the PMCPA deemed these likes as constituting public promotion of the drug, violating UK pharmaceutical marketing regulations. Similarly, GSK employees liked a post about the U.S. indication expansion for the cancer drug Jemperli (dostarlimab), despite the drug not being approved in Europe. These actions, under UK regulations, were considered indirect promotion of prescription drugs, breaching industry rules.

Notably, even a simple interaction like a "like" can prompt regulatory investigations. Reports indicate that these violations are not isolated incidents. AstraZeneca has faced multiple similar violations, suggesting a risk of "disregarding compliance culture," while GSK, despite acknowledging some violations, has attempted to mitigate responsibility, indicating a lack of understanding of the complexities of global compliance.

These incidents reflect potential deep-seated issues in the culture and governance of UK pharmaceutical companies. Such issues not only affect internal stability but also directly impact the credibility of the entire industry. Public trust in the pharmaceutical industry is built on high expectations of ethical conduct.

Examining the performance of these multinational pharmaceutical companies in our country reveals that similar problems have long existed. For instance, AstraZeneca and GSK have faced severe penalties due to bribery scandals related to medical insurance approvals and market promotions. These events highlight an excessive pursuit of profit and a disregard for local rules and culture. As global pharmaceutical giants, their actions not only affect their own interests but also profoundly influence industry culture. Any ethical lapse raises public doubts about the pharmaceutical industry's original intentions, undermining patient trust in science and efficacy.

UK regulations on pharmaceutical marketing are known for their strictness; even a "like" on LinkedIn could be viewed as public marketing, triggering regulatory investigations. This level of rigor prompts us to reflect on whether enough attention is given to compliance and ethical details in our pharmaceutical marketing environment.

The LinkedIn incident reminds us that in the digital age, every public interaction may be subject to scrutiny. In our country, many pharmaceutical marketers may not yet realize that casual behavior on social media could trigger regulatory red flags. The Internet's nature is one of lasting memory, so we must respect the detailed investigations and strict enforcement by UK regulatory bodies regarding violations, which may serve as a reference for our relevant departments.

Faced with the dual challenges of globalization and digitization, pharmaceutical industry professionals must remember their responsibilities. Whether in product promotion or public communication, patient interests and social responsibility should be at the core. On the path of compliance, we must proceed with caution to avoid falling into ethical and regulatory dilemmas. In the digital world, no detail is too trivial. For the pharmaceutical industry, the most critical bottom line is how we uphold the bottom line of "trust."